Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosfomycin intravenous - Nabriva Therapeutics

Next Previous
Drug Profile

Fosfomycin intravenous - Nabriva Therapeutics

Alternative Names: CONTEPO; Fosfomycin disodium; Fosfomycin for injection - Nabriva Therapeutics; IV fosfomycin - Nabriva Therapeutics; ZOLYD; ZTI-01

Latest Information Update: 27 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zavante Therapeutics
  • Developer Nabriva Therapeutics; National Institute of Allergy and Infectious Diseases; Zavante Therapeutics
  • Class Anti-infectives; Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules; Urinary anti-infective agents
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Urinary tract infections
  • Phase II Intra-abdominal infections; Skin and soft tissue infections
  • No development reported Bacterial infections; Gram-negative infections; Nosocomial infections

Most Recent Events

  • 18 Jul 2024 Nabriva Therapeutics announces intention to re-submit NDA to the US FDA for Urinary tract infections (Complicated), before June 2022, in the US
  • 18 Jul 2024 Meitheal Pharmaceuticals acquires Fosfomycin intravenous from Nabriva Therapeutics in North America
  • 18 Jul 2024 Nabriva expects decision for New drug application (NDA) from the US FDA later in 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top